Data integrity is ‘biggest issue’ for drug, API firms during inspections, FDA official says
Regulatory NewsJeff Craven
Audit/inspectionGenericsGlobalGMPNorth AmericaOTCPharmaceuticalsUS Food and Drug Administration (FDA)Warning lettersRegulatory NewsJeff CravenAudit/inspectionGenericsGlobalGMPNorth AmericaOTCPharmaceuticalsUS Food and Drug Administration (FDA)Warning letters